Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases.

Authors :: Chen Y
Sun J
Liu H
Yin G
Xie Q
Source :: Journal of immunology research [J Immunol Res] 2019 Dec 31; Vol. 2019, pp. 5727516. Date of Electronic Publication: 2019 Dec 31 (Print Publication: 2019).
Publication Year :: 2019
Abstract: Chimeric antigen receptor T (CAR-T) cells are T cells engineered to express specific synthetic antigen receptors that can recognize antigens expressed by tumor cells, which after the binding of these antigens to the receptors are eliminated, and have been adopted to treat several kinds of malignancies. Autoimmune diseases (AIDs), a class of chronic disease conditions, can be broadly separated into autoantibody-mediated and T cell-mediated diseases. Treatments for AIDs are focused on restoring immune tolerance. However, current treatments have little effect on immune tolerance inverse; even the molecular target biologics like anti-TNF α inhibitors can only mildly restore immune balance. By using the idea of CAR-T cell treatment in tumors, CAR-T cell-derived immunotherapies, chimeric autoantibody receptor T (CAAR-T) cells, and CAR regulatory T (CAR-T) cells bring new hope of treatment choice for AIDs.<br />Competing Interests: The authors declare that they have no conflicts of interest.<br /> (Copyright © 2019 Yuehong Chen et al.)